Agios Pharma (AGIO) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Agios Reports Business Highlights and First Quarter 2021 Financial Results
April 29, 2021 7:00 AM EDTData from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency and Phase 2 Study of Mitapivat in Thalassemia Accepted for Presentation at EHA 2021 Virtual Congress
Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021
Sale of Oncology Portfolio to Servier Closed on March 31; Agios Received $1.8 Billion Upfront Payment to Accelerate and Expand Genetically Defined Disease Portfolio
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Agios... More
